THE WHAT? Coty has announced that it now expects to receive a shareholder distribution of US$250 million at a minimum from its equity stake in Wella, significantly above the previously announced US$175 million.
THE DETAILS The US beauty behemoth expects to receive this shareholder distribution in the next two months and intends to use it, plus extra cash on the balance sheet to redeem its 2023 €550 million unsecured bonds in full, after the bond call premium drops to pay on April 15, 2022.
THE WHY? The upsized shareholder distribution is due to Wella finalizing the intended use of proceeds from its recent refinancing.
Sue Y. Nabi, Coty’s Chief Executive Officer, stated, “Deleveraging our balance sheet remains a key priority at Coty and a driver of further value expansion. Following our strong deleveraging progress during 2Q22, the expected upsized shareholder distribution from Wella should be a meaningful step in the further reduction of debt.
While we continue to monitor global market conditions, I am very encouraged by our LFL revenue trends quarter-to-date. We remain confident in our guidance for mid-teens LFL sales growth in 3Q22, assuming no significant deterioration in the demand backdrop. This is further evidence that our decision to step-up marketing reinvestment in 2Q22 is having the intended effect of accelerating our sales growth, and is an additional proof point of the virtuous cycle we have created.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
